MBX
MBX Biosciences, Inc.
$40.97
+18.02%
2026-05-08
About MBX Biosciences, Inc.
MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is Canvuparatide (MBX 2109), a parathyroid hormone peptide prodrug, which is in Phase 3 clinical trial for the treatment of chronic hypoparathyroidism. The company is also developing Imapextide (MBX 1416), a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 2 clinical trial a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. In addition, it is developing MBX 4291, a lead obesity product candidate, which is in investigational new drug-enabling studies for the treatment of obesity and co-morbidities. The company was founded in 2018 and is based in Carmel, Indiana.
Key Fundamentals
P/E Ratio
4.51
Forward P/E
-8.81
EPS (TTM)
$-2.17
ROE
-24.4%
Profit Margin
0.0%
Debt/Equity
0.16
Price/Book
4.39
Market Cap
$1.72B
Avg Volume (10D)
480K
Recent Breakout Signals
Recent Price Range (60 Days)
60D High
$41.28
60D Low
$26.14
Avg Volume
515K
Latest Close
$40.97
Get breakout alerts for MBX
Sign up for Breakout Scanner to receive daily notifications when MBX triggers breakout signals. Build custom AI screeners and backtest strategies.
Start Free Trial7-day free trial. No card required.
MBX Biosciences, Inc. (MBX) is listed on the NASDAQ (NASDAQ). Breakout Scanner monitors MBX daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. MBX operates in the Healthcare sector within the Biotechnology industry. Data is provided for informational purposes only and does not constitute financial advice.